R46
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- ALLOGRAFT_REJECTION+0.530
- INTERFERON_GAMMA_RESPONSE+0.490
- INFLAMMATORY_RESPONSE+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- IL2_STAT5_SIGNALING+0.390
- BILE_ACID_METABOLISM+0.330
- TNFA_SIGNALING_VIA_NFKB+0.330
- COMPLEMENT+0.310
- XENOBIOTIC_METABOLISM+0.290
Top 10 suppressed
- G2M_CHECKPOINT-0.520
- E2F_TARGETS-0.510
- PROTEIN_SECRETION-0.450
- MITOTIC_SPINDLE-0.430
- MYC_TARGETS_V1-0.410
- MTORC1_SIGNALING-0.320
- ANDROGEN_RESPONSE-0.290
- PI3K_AKT_MTOR_SIGNALING-0.250
- PANCREAS_BETA_CELLS-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M8M56Z4Y | pilocytic astrocytoma | — | 0.880 |
| 2 | R194 | — | — | 0.852 |
| 3 | TCGA-AC-A3BB-01A-21R-A19W-07 | — | A | 0.845 |
| 4 | 97431f78-eea7-4799-8493-0ea4164a432b | — | — | 0.840 |
| 5 | BS_4BWB0FA0 | low-grade glioma | — | 0.838 |
| 6 | BS_DSS3S5XD | low-grade glioma | — | 0.836 |
| 7 | MDT-AP-1152 | Med | Medulloblastoma | 0.835 |
| 8 | TCGA-A7-A4SA-01A-11R-A266-07 | — | A | 0.832 |
| 9 | TCGA-AC-A2FE-01A-11R-A19W-07 | — | A | 0.831 |
| 10 | TCGA-FD-A43S-01A-21R-A23W-07 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |